When should semaglutide (Ozempic) be discontinued prior to a scheduled knee surgery?

When to Stop Ozempic (Semaglutide) Before Knee Surgery

For elective knee surgery, discontinue Ozempic at least 3 weeks (approximately 3 half-lives) before the procedure to minimize aspiration risk, particularly if you are using it for weight loss rather than diabetes management. 1, 2

Pharmacokinetic Rationale

• Semaglutide (Ozempic) has a half-life of approximately 7 days (one week) 1
• Stopping for 3 half-lives clears approximately 88% of the drug from the system, which translates to roughly 3 weeks or 21 days 1
• This extended cessation period is necessary because delayed gastric emptying persists even after the drug is partially cleared 1

Risk-Stratified Cessation Recommendations

For Patients Using Ozempic for Weight Loss (Non-Diabetic)

• Mandatory cessation: 3 weeks (21 days) before surgery 1, 2
• This population faces higher aspiration risk without the glycemic control benefits that justify continued use 1
• Higher doses used for weight management may cause more prolonged gastric stasis 1

For Patients Using Ozempic for Type 2 Diabetes

• Preferred approach: 3 weeks cessation if feasible 1, 2
• Minimum acceptable: 1 week (one dosing interval) if glycemic control concerns outweigh aspiration risk 2
• Consult endocrinology immediately to arrange bridging therapy with short-acting insulin during the cessation period 2
• The benefits of continued glycemic control and potential reduction in postoperative cardiac events must be weighed against aspiration risk 1

Critical Aspiration Risk Considerations

• GLP-1 receptor agonists cause delayed gastric emptying, increasing pulmonary aspiration risk during anesthesia 1, 2
• One 2025 study reported an odds ratio of 10.23 for pulmonary aspiration in patients on GLP-1 receptor agonists undergoing elective surgery 2
• Discontinuing for only 7 days does not reliably ensure an empty stomach preoperatively 1
• Patients on long-term therapy may experience some tachyphylaxis (reduced gastric-emptying effects), potentially lowering risk 2

High-Risk Scenarios Requiring Longer Cessation

Stop Ozempic for the full 3 weeks if any of the following apply:

• General anesthesia planned (versus regional/spinal anesthesia) 2
• Recently started medication or dose escalation within the past few months 1
• Active symptoms: nausea, vomiting, or abdominal distention 1
• Concurrent medications that delay gastric emptying: opioids, proton pump inhibitors, tricyclic antidepressants 1
• Recent recreational drug use: alcohol or cannabis 1
• History of gastro-esophageal surgery 1

Glycemic Management During Cessation (Diabetic Patients)

• Target intra-operative glucose: 100-180 mg/dL 2
• Pre-operative HbA1c goal: <8% for elective procedures 2
• Coordinate with endocrinology to establish short-acting insulin regimen as bridge therapy 2
• Monitor blood glucose every 2-4 hours while NPO, using rapid-acting insulin as needed 2
• For context: metformin is held only on surgery day, SGLT2 inhibitors 3-4 days before, and other oral agents the morning of surgery 2

Additional Risk Mitigation Strategies

If the 3-week cessation is not possible:

• Consider postponing surgery to allow adequate washout time 1
• Implement clear liquid diet for an extended period before standard NPO fasting 1
• Administer prokinetic agents (metoclopramide or erythromycin) preoperatively 1
• Plan for aspiration precautions: rapid sequence intubation, airway protection measures 1
• Perform pre-operative gastric ultrasonography to assess retained gastric contents 1

Post-Operative Resumption

• Restart Ozempic once the patient tolerates oral intake and gastrointestinal function has normalized 2
• The FDA label does not specify post-operative resumption timing, but clinical practice supports waiting for normal GI function 3

Common Pitfalls to Avoid

• Do not assume 1 week is sufficient for weight-loss patients—the 3-week rule applies 1
• Do not continue Ozempic until the day before surgery without careful risk assessment and aspiration precautions 1
• Do not stop diabetic patients' Ozempic without arranging alternative glycemic control—this can lead to dangerous hyperglycemia 2
• Do not ignore recent dose escalations—these patients have higher aspiration risk even with adequate cessation time 1

Evidence Quality Note

Current recommendations are based on expert consensus and extrapolation from GLP-1 receptor agonist pharmacology rather than robust randomized trial data specific to perioperative management 1, 2. The American Diabetes Association explicitly acknowledges "little data on the safe use" of GLP-1 receptor agonists in the perioperative period 2. Despite this limitation, the aspiration risk is sufficiently documented to warrant conservative cessation practices.